RightFit
Not yet recruitingPhase not listed

Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.

Who can join

As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.

Age
18 Years to 65 Years
Sex
All sexes
Healthy volunteers
Not accepted
Compensation
Not stated

Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.

What to expect

No one can promise a trial will help you personally — that is what the research is trying to find out.

What participation involves

Not stated in the study description — ask the study team about visits and procedures.

Compensation
Not stated
  • Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
  • Participants are monitored closely by the research team throughout the study.
  • Some participants may receive access to an investigational treatment, which is still being studied.
  • Your participation helps researchers learn whether this approach could help future patients.

About this study

The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the following: 1. Improvement in capillary blush, reduce the tapering and tortuosity of affected vessels on pulmonary wedge angiography and decreased wall thickness on intravascular ultrasound in previously affected areas. 2. Improvement in previously poorly or non-perfused areas rather than increased perfusion to previously perfused areas. 3. No changes in baseline ventilation and improvement and ventilation/perfusion matching.

Compensation is read from the study's own description and may be missing — always confirm with the study team.

Eligibility

Official eligibility criteria

Inclusion Criteria - Feasibility Group: * Group 1 Pulmonary Hypertension (G1PH)-must be idiopathic, drug induced, or hereditary (D/H/I) * Age \< 65 years at time of diagnosis * Must be 18 years of age or older Inclusion Criteria - "Real-world" treatment naïve cohort: * Group 1 Pulmonary Hypertension (G1PH)-all types * Must be treatment naïve * Must be 18 years of age or older Inclusion Criteria - "Real-world" prevalent cohort: * Group 1 Pulmonary Hypertension (G1PH)-all types * Must be 18 years of age or older Exclusion Criteria: * Contraindication to right heart catheterization (per PI) * Prior exposure to sotatercept * Hemoglobin \> 18 g/dL at screening * Estimated GFR \< 30 mL/min at screening * Platelet count \<30 at screening * Positive pregnancy test

Study sites (1)

AZ